Corona remedies to expand Bhayala facility at a cost of Rs. 400 million
Manufacturing
Jan 31,2026
Corona Remedies has announced a Rs. 400 million expansion of its Bhayala manufacturing facility to enhance production capacity.
The investment is aimed at meeting growing demand across key therapeutic segments in domestic and export markets.
The expansion will also support backward integration and operational efficiency.
This move reflects continued capital investment by Indian pharma companies amid sustained healthcare demand.
Company :
|
Corona Remedies